Conestoga Capital Advisors LLC Has $61.99 Million Holdings in Simulations Plus, Inc. (NASDAQ:SLP)

Conestoga Capital Advisors LLC reduced its stake in Simulations Plus, Inc. (NASDAQ:SLP) by 14.5% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,935,848 shares of the technology company’s stock after selling 327,816 shares during the period. Conestoga Capital Advisors LLC owned 9.67% of Simulations Plus worth $61,986,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. nVerses Capital LLC grew its stake in shares of Simulations Plus by 1,100.0% in the third quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock worth $38,000 after purchasing an additional 1,100 shares during the last quarter. EntryPoint Capital LLC bought a new position in Simulations Plus in the 1st quarter valued at $57,000. Allspring Global Investments Holdings LLC purchased a new stake in shares of Simulations Plus during the 1st quarter valued at $70,000. US Bancorp DE increased its position in shares of Simulations Plus by 37.0% in the third quarter. US Bancorp DE now owns 4,974 shares of the technology company’s stock valued at $159,000 after acquiring an additional 1,343 shares during the period. Finally, Connecticut Wealth Management LLC bought a new stake in shares of Simulations Plus during the 1st quarter valued at about $204,000. Institutional investors and hedge funds own 78.08% of the company’s stock.

Insider Transactions at Simulations Plus

In other news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $31.26, for a total transaction of $625,200.00. Following the completion of the transaction, the director now directly owns 3,481,592 shares of the company’s stock, valued at $108,834,565.92. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have sold 40,750 shares of company stock valued at $1,352,455. 20.90% of the stock is owned by insiders.

Simulations Plus Price Performance

NASDAQ SLP traded up $0.45 on Friday, reaching $27.67. The company had a trading volume of 54,180 shares, compared to its average volume of 132,192. The firm has a 50-day moving average of $32.46 and a 200-day moving average of $40.10. Simulations Plus, Inc. has a 1 year low of $27.22 and a 1 year high of $51.22. The firm has a market capitalization of $553.68 million, a PE ratio of 55.55 and a beta of 0.69.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. Simulations Plus had a return on equity of 6.16% and a net margin of 14.15%. The company had revenue of $18.70 million during the quarter, compared to analysts’ expectations of $19.73 million. During the same quarter in the prior year, the business posted $0.18 earnings per share. The company’s revenue for the quarter was up 19.9% compared to the same quarter last year. As a group, sell-side analysts expect that Simulations Plus, Inc. will post 1.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on SLP. BTIG Research reduced their target price on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a report on Thursday, October 24th. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Thursday, October 24th. JMP Securities assumed coverage on shares of Simulations Plus in a report on Tuesday, July 16th. They issued a “market perform” rating for the company. Finally, KeyCorp started coverage on shares of Simulations Plus in a research report on Monday, July 29th. They set an “overweight” rating and a $47.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.50.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.